New hope for rare blood cancer: targeted drug shows promise in early trial
NCT ID NCT03485547
First seen Feb 02, 2026 · Last updated Apr 28, 2026 · Updated 12 times
Summary
This early-phase study tested the drug venetoclax in 5 adults with a rare and aggressive blood cancer called BPDCN that had come back or not responded to prior treatment. The goal was to find a safe dose and see if the drug could shrink or control the cancer. Because BPDCN often requires ongoing therapy, this approach aims to manage the disease rather than cure it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.